0
You can inhibit a receptor by either of 2 ways, one being specific one being not so specific. First of all if you have kinases they have a DNA binding domain as well as a catalytic region and ATP region.
First you have to identify what you cell has for receptors this may be difficult because .01% of the cells mass are these receptors. Most identified by recomiant DNA, so you can find them by there DNA binding conserved sequence. Not all of them also have to be on the surface some maybe in the cytosol of the protien.
So you can make a specific inhibitors for there receptor domain because these are specific. For cancer you want a dirty inhibitor to inhibit a lot of kinases.
Inhibition of a receptor can occur through binding of an antagonist molecule that blocks the active site, downregulation of receptor expression, or post-translational modifications that impair receptor function. These mechanisms prevent the receptor from recognizing and responding to its ligand, leading to decreased signaling activity.
Add your answer:
Earn +20 pts
Which molecule covers the binding site?
Proteins can cover the binding site of a receptor and prevent another molecule from binding to it. This interaction can inhibit the receptor's activity and affect cellular signaling pathways.
Neurotransmitters bind to specific proteins on the postsynaptic membrane called?
Neurotransmitters bind to specific proteins on the postsynaptic membrane called receptors. These receptors initiate a series of events that can either excite or inhibit the firing of the postsynaptic neuron.
Which factor would most likely interfere with the binding of a ligand to an intracellular receptor?
The presence of other molecules competing for binding to the receptor would most likely interfere with the binding of a ligand to an intracellular receptor. The receptor may also be in an incorrect conformational state that prevents ligand binding. Lastly, alterations in the receptor's structure due to mutations could interfere with ligand binding.
What is the importance of Receptor-mediated Endocytosis in the genetic disorder Familial Hyper-Cholesterolemia?
Receptor-mediated endocytosis is important in Familial Hypercholesterolemia (FH) because it is the mechanism by which LDL cholesterol is taken up by cells. In FH, a mutation in the LDL receptor gene leads to reduced uptake of LDL, causing elevated blood cholesterol levels. This impairment in receptor-mediated endocytosis results in an increased risk of cardiovascular disease in individuals with FH.
What would be least affected by defective receptor proteins on a cell membrane?
The transport of nutrients and waste across the cell membrane would be least affected by defective receptor proteins. This is because transport proteins, not receptor proteins, are primarily responsible for moving molecules across the cell membrane.
What are the effects of dopamine receptor antagonists?
They inhibit the expression of dopamine.
Which molecule covers the binding site?
Proteins can cover the binding site of a receptor and prevent another molecule from binding to it. This interaction can inhibit the receptor's activity and affect cellular signaling pathways.
How a drug interacts with a receptor?
A drug interacts with a receptor by binding to specific sites on the receptor, leading to changes in the conformation or activity of the receptor. This interaction can either activate or inhibit the receptor's function, ultimately affecting downstream signaling pathways and physiological responses within the body. The strength and specificity of this interaction determine the drug's effectiveness and potential side effects.
How would caffeine binding to an adenosine receptor affect the activity inside the neuron?
Caffeine binding to an adenosine receptor would block adenosine from binding to the receptor, preventing the normal inhibitory effect of adenosine on neuronal activity. This results in increased neural firing and the release of neurotransmitters such as dopamine and glutamate, leading to increased alertness and arousal.
What are anticholinergics?
Anticholinergics are a class of medications that inhibit parasympathetic nerve impulses by selectively blocking the binding of the neurotransmitter acetylcholine to its receptor in nerve cells.
Neurotransmitters bind to specific proteins on the postsynaptic membrane called?
Neurotransmitters bind to specific proteins on the postsynaptic membrane called receptors. These receptors initiate a series of events that can either excite or inhibit the firing of the postsynaptic neuron.
What happens to ACh once it has bound to its receptor?
Once acetylcholine (ACh) binds to its receptor, it can either stimulate or inhibit the activity of the cell. This activation triggers a cellular response, such as muscle contraction or nerve cell communication. After its action, ACh is rapidly broken down by the enzyme acetylcholinesterase to terminate the signal.
A receptor that contains many mechanically gated ion channels would function best as?
tactile receptor
How would you change the pA2 for a drug-receptor pair?
The only way to change the pA2 would be to alter the nature of the receptor, because the pA2 is essentially a measurement of the affinity of the antagonist drug for the receptor. So, in order to change this value, one would need to change the receptor in a way that changes the binding affinity of the drug.
Can you write a sentence using inhibit?
The medication is designed to inhibit the growth of bacteria in the body.
Why Fresh frozen plasma is given to patients with dengue instead of platelet?
fresh frozen plasma by Fc receptor blockade will inhibit immune mediated destruction of platelets and thereby increase the platelet count
Which factor would most likely interfere with the binding of a ligand to an intracellular receptor?
The presence of other molecules competing for binding to the receptor would most likely interfere with the binding of a ligand to an intracellular receptor. The receptor may also be in an incorrect conformational state that prevents ligand binding. Lastly, alterations in the receptor's structure due to mutations could interfere with ligand binding.
